期刊文献+

ERCC1在胃癌组织中的表达及其对含铂类辅助化疗疗效的影响 被引量:2

ERCC1 expression in gastric carcinoma tissue and its influence on efficacy of adjuvant chemotherapeutic regimens containing platinum
下载PDF
导出
摘要 目的探讨ERCC1在胃癌组织中的表达及对含铂类辅助化疗患者无病生存期(DFS)和总生存期(OS)的影响。方法收集34例胃癌根治术后患者的临床及病理资料,应用免疫组织化学方法检测ERCC1在胃癌组织中的表达,采用SPSS18.0软件进行统计学分析,χ2检验分析ERCC1表达与临床特征的相关性,Kaplan-Meier方法分析ERCC1表达对含铂类辅助化疗患者生存期的影响。结果 ERCC1表达与肿瘤发病部位、大小、浸润深度、组织学类型、淋巴结转移、TNM分期无关。ERCC1表达阳性者DFS 11个月,中位OS 20个月;ERCC1阴性表达者DFS14.5个月,中位OS为23.5个月。ERCC1阳性表达患者与阴性表达患者比较,DFS差异无显著性意义(P>0.05),中位OS差异有显著性意义(P<0.05)。结论胃癌ERCC1的表达与临床特征不相关,可以作为胃癌根治术后接受含铂类辅助化疗疗效的预测指标。 Objective To investigate the expression of ERCCI in gastric cancer tissue and its influence on diseasefree survival (DFS) and overall survival (OS) of the patients who underwent adjuvant chemotherapies with regimen containing platinum. Methods Thirty-four patients with gastric cancer post to radical operation were inch,deal into this relrospective study, ERCC1 expression in tumor were detected with immunohistochemistry (IHC) , and chi -square - lest was used to analyze the correlation between ERCC1 expression and clinical features. Kaplan - Meier analysis was used to analyze the influence of ERCC1 expression on survivals of patients treated with adjuvant chemotherapy with regimens cnntaining platinum. SPSSI8.0 was used for statistics. Results ERCCI expression was found not correlated to features of the primary lumor such as location, size, infiltration depth or histology, lymph node metastasis, or TNM stage. DFS and median OS were observed to be 11 and 20 months respectively in patients positive in ERCC1 expression, in contrast to 14.5 and 23.5 months in those negative. Compared with ERCC1 positive patients, the negatives had the significant difference in median OS ( P 〈0.05 ) bt,t not in DFS ( P 〉0.05 ). Conclusion ERCCI expression dose not correlate Io elinical features in gastric cancer patients, hut it can be used as a marker predicting efficacy for patienls with gastric, cancer post to operation treated with adjuvant regimens containing the platinum.
出处 《大连医科大学学报》 CAS 2013年第2期119-122,共4页 Journal of Dalian Medical University
基金 大连市科技基金(2010E15SF002)
关键词 胃癌 ERCC1 预后 gastric cancer ERCC1 prognosis
  • 相关文献

参考文献6

  • 1Bang Y-J, Kim Y-W, Yang H-K,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gas- trectomy (CLASSIC) :a phase 3 open- label, randomized controlled trial [ J ]. The Lancet, 2012, 379 : 315 - 321.
  • 2Liu Y - P, Ling Y, Qi Q - F, et al. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer celXs to pXatinum agents and survival in gastric cancer pa- tients treated with oxalipiatin - based adjuvant chemothera- py[J]. Oncol Lett, 2013,5(3) :935 -942.
  • 3Rosell R, Taron M, Aberola V, et al. Genetic testing for chemotherapy in non- small- cell lung cancer [ J ]. Lung Cancer, 2003,41 ( 1 ) :97 - 102. anced gas- tric cancer[ J]. Sr J Cancer,2008,98 (4) :832 - 839.
  • 4Vilmar AC, Santoni Rugiu E, Sorensen JB. ERCC1 and histo- pathology in advanced NSCLC patients randomized in a large multieenter phase Ⅲ trial[ J]. Ann Oneol,2010, 21 (9) : 1817 - 1824.
  • 5Kim MK,Cho K J, Kwon GY, et al. ERCC1 predicting ehe- moradiation resistance and poor outcome in oesophageal cancer[J]. Eur J Cancer,2008,44( 1 ) :54 -60.
  • 6Matsubara J, Nishina T, Yamada Y, et al. Impacts of exci- sion repair cross - complementing gene 1 (ERCC1) , dihy- dropyrimi- dine dehydrogenase, and epidermal growth fac- tor receptor on the outcomes of patients with advanced gas- tric cancer [ J ]. Sr J Cancer,2008,98 (4) : 832 - 839.

同被引文献39

  • 1胃癌诊疗规范(2011年版)[J].中国医学前沿杂志(电子版),2012,4(5):62-71. 被引量:244
  • 2杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1480
  • 3Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin,2014,64(1) : 9-29.
  • 4Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair dross-comple- mentation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemo- therapy[J]. Clin Cancer Res, 2004,10(15) : 4939- 4943.
  • 5Tepeli E,Caner V,Biiytikpmarbas11 N,et al. Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer [J]. Mol Biol Rep,2012,39(1) :335-341.
  • 6Chen S, Zhang J, Wang R, et al. The platinum-based treatments for advanced non-small cell lung cancer,is low/negative ERCC1 ex- pression better than high/positive ERCC1 expression A meta-analy- sis[J].Lung Cancer,2010,70(1) :63-70.
  • 7Friboulet L,Postel-Vinay S,Sourisseau T, et al. ERCC1 function in nuclear excision and interstrand erosslink repair pathways is media- ted exclusively by the ERCC1-202 isoform[J]. Cell Cycle, 2013,12 (20) : 3298- 3306.
  • 8Yu D, Zhang X, Liu J, et al. Charcterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis[J]. Clin Cancer Resistance, 2008,14 (9) : 2878- 2886.
  • 9Mcwhir J, Seirridge J, Harrison D J, et al. Mice with DNA repair gene(ERCC-1) deficiency have elevated levels of p53,1iver nuclear abnormalities and die before weaning[J]. Nat Genet, 1993,5 (3) : 217-224.
  • 10Lima L M,de Souza L R,da Silva T F, et al. DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism ( G19007 A ), protein expression and association with epidemiological and clinicopatho- logical factors[J]. Histopathology, 2012,60(3) : 489- 496.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部